GlaxoSmithKline PLC Stock Options Expiring on 16th of January 2026
| GSK Stock | USD 34.31 0.18 0.53% |
GlaxoSmithKline PLC's latest option contracts expiring on 2026-01-16 are carrying combined implied volatility of 0.31 with a put-to-call open interest ratio of 0.25 over 33 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on 2026-01-16. The total put volume is at 167, with calls trading at the volume of 167. This yields a 0.23 put-to-call volume ratio.
Open Interest Against 2026-01-16 Option Contracts
2026-01-16
The chart above shows GlaxoSmithKline PLC's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. GlaxoSmithKline PLC's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for GlaxoSmithKline PLC's option, there is no secondary market available for investors to trade.
GlaxoSmithKline PLC Maximum Pain Price across 2026-01-16 Option Contracts
GlaxoSmithKline PLC's max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthless.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
GlaxoSmithKline PLC ADR In The Money Call Balance
When GlaxoSmithKline PLC's strike price is surpassing the current stock price, the option contract against GlaxoSmithKline PLC ADR stock is said to be in the money. When it comes to buying GlaxoSmithKline PLC's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on GlaxoSmithKline PLC ADR are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
GlaxoSmithKline Current Options Market Mood
GlaxoSmithKline PLC's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps GlaxoSmithKline Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Most options investors, including buyers and sellers of GlaxoSmithKline PLC's calls and puts, are not very successful. It is estimated that an average options trader loses somewhere between 80% to 90% of the time. GlaxoSmithKline PLC's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current GlaxoSmithKline contract
Base on the Rule 16, the options market is currently suggesting that GlaxoSmithKline PLC ADR will have an average daily up or down price movement of about 0.0194% per day over the life of the 2026-01-16 option contract. With GlaxoSmithKline PLC trading at USD 34.31, that is roughly USD 0.006648. If you think that the market is fully incorporating GlaxoSmithKline PLC's daily price movement you should consider buying GlaxoSmithKline PLC ADR options at the current volatility level of 0.31%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
GlaxoSmithKline |
GlaxoSmithKline PLC Option Chain
When GlaxoSmithKline PLC's strike price is surpassing the current stock price, the option contract against GlaxoSmithKline PLC ADR stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
2024-12-062024-12-132024-12-202024-12-272025-01-032025-01-172025-02-212025-05-162026-01-162027-01-15
GlaxoSmithKline PLC's option chain is a display of a range of information that helps investors for ways to trade options on GlaxoSmithKline. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for GlaxoSmithKline. It also shows strike prices and maturity days for a GlaxoSmithKline PLC against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Expiration | Current Spread | Last Price | |||
Call | GSK Option Call 16-01-2026 18 | 64 | 2026-01-16 | 14.8 - 17.7 | 15.6 | In |
Call | GSK Option Call 16-01-2026 20 | 32 | 2026-01-16 | 13.6 - 14.3 | 13.9 | In |
Call | GSK Option Call 16-01-2026 23 | 21 | 2026-01-16 | 11.3 - 11.6 | 11.0 | In |
Call | GSK Option Call 16-01-2026 25 | 15 | 2026-01-16 | 9.2 - 12.0 | 9.83 | In |
Call | GSK Option Call 16-01-2026 28 | 7 | 2026-01-16 | 7.1 - 7.4 | 7.3 | In |
Call | GSK Option Call 16-01-2026 30 | 226 | 2026-01-16 | 5.7 - 5.9 | 5.49 | In |
Call | GSK Option Call 16-01-2026 33 | 261 | 2026-01-16 | 3.8 - 4.1 | 3.68 | In |
Call | GSK Option Call 16-01-2026 35 | 223 | 2026-01-16 | 2.85 - 3.1 | 2.93 | Out |
Call | GSK Option Call 16-01-2026 37 | 10799 | 2026-01-16 | 2.1 - 2.3 | 2.3 | Out |
Call | GSK Option Call 16-01-2026 40 | 1204 | 2026-01-16 | 1.35 - 1.45 | 1.41 | Out |
Call | GSK Option Call 16-01-2026 42 | 1235 | 2026-01-16 | 0.8 - 1.1 | 1.02 | Out |
Call | GSK Option Call 16-01-2026 45 | 1853 | 2026-01-16 | 0.55 - 0.65 | 0.6 | Out |
Call | GSK Option Call 16-01-2026 47 | 446 | 2026-01-16 | 0.3 - 0.55 | 0.43 | Out |
Call | GSK Option Call 16-01-2026 50 | 1749 | 2026-01-16 | 0.2 - 0.35 | 0.26 | Out |
Call | GSK Option Call 16-01-2026 55 | 470 | 2026-01-16 | 0.05 - 0.4 | 0.15 | Out |
Call | GSK Option Call 16-01-2026 60 | 87 | 2026-01-16 | 0.0 - 0.3 | 0.1 | Out |
Call | GSK Option Call 16-01-2026 65 | 439 | 2026-01-16 | 0.0 - 0.3 | 0.1 | Out |
Put | GSK Option Put 16-01-2026 18 | 87 | 2026-01-16 | 0.0 - 0.35 | 0.15 | Out |
Put | GSK Option Put 16-01-2026 20 | 21 | 2026-01-16 | 0.1 - 0.4 | 0.32 | Out |
Put | GSK Option Put 16-01-2026 23 | 45 | 2026-01-16 | 0.35 - 0.5 | 0.45 | Out |
Put | GSK Option Put 16-01-2026 25 | 97 | 2026-01-16 | 0.55 - 0.7 | 0.7 | Out |
Put | GSK Option Put 16-01-2026 28 | 412 | 2026-01-16 | 1.05 - 1.25 | 1.07 | Out |
Put | GSK Option Put 16-01-2026 30 | 265 | 2026-01-16 | 1.55 - 1.75 | 1.8 | Out |
Put | GSK Option Put 16-01-2026 33 | 516 | 2026-01-16 | 2.55 - 2.9 | 2.93 | Out |
Put | GSK Option Put 16-01-2026 35 | 1399 | 2026-01-16 | 3.5 - 4.9 | 4.0 | In |
Put | GSK Option Put 16-01-2026 37 | 541 | 2026-01-16 | 4.6 - 5.0 | 5.1 | In |
Put | GSK Option Put 16-01-2026 40 | 591 | 2026-01-16 | 6.7 - 7.2 | 7.5 | In |
Put | GSK Option Put 16-01-2026 42 | 253 | 2026-01-16 | 8.2 - 11.0 | 8.9 | In |
Put | GSK Option Put 16-01-2026 45 | 445 | 2026-01-16 | 11.0 - 11.4 | 10.6 | In |
Put | GSK Option Put 16-01-2026 47 | 78 | 2026-01-16 | 12.9 - 13.2 | 10.6 | In |
Put | GSK Option Put 16-01-2026 50 | 0 | 2026-01-16 | 14.1 - 18.5 | 17.0 | In |
Put | GSK Option Put 16-01-2026 55 | 16 | 2026-01-16 | 18.7 - 21.2 | 18.5 | In |
Put | GSK Option Put 16-01-2026 60 | 52 | 2026-01-16 | 25.3 - 28.9 | 20.9 | In |
GlaxoSmithKline PLC Market Cap Over Time
Market Cap |
| Timeline |
GlaxoSmithKline Total Stockholder Equity
Total Stockholder Equity |
|
GlaxoSmithKline PLC Corporate Directors
| Lynn Elsenhans | Independent Non-Executive Director | Profile | |
| Harry Dietz | Non-Executive Independent Director, Scientific and Medical Expert | Profile | |
| Charles Bancroft | Non-Executive Independent Director | Profile | |
| Vivienne Cox | Independent Non-Executive Director and Workforce Engagement Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.28) | Dividend Share 0.61 | Earnings Share 1.54 | Revenue Per Share 15.38 | Quarterly Revenue Growth (0.02) |
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.